---
title: "Brimonidine - Rosacea"
sidebar: mydoc_sidebar
permalink: db00484-mesh-d012393-1.html
toc: false 
---


Path ID: `DB00484_MESH_D012393_1`
{% include image.html url="images/db00484-mesh-d012393-1.png" file="db00484-mesh-d012393-1.png" alt="db00484-mesh-d012393-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| <a href="https://identifiers.org/MESH:D000068438">MESH:D000068438 </a> | brimonidine | Drug |
| <a href="https://identifiers.org/UniProt:P08913">UniProt:P08913 </a> | Alpha-2A adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18089">UniProt:P18089 </a> | Alpha-2B adrenergic receptor | Protein |
| <a href="https://identifiers.org/UniProt:P18825">UniProt:P18825 </a> | Alpha-2C adrenergic receptor | Protein |
| <a href="https://identifiers.org/reactome:R-HSA-418594">reactome:R-HSA-418594 </a> | G alpha (i) signalling events | Pathway |
| <a href="https://identifiers.org/reactome:R-HSA-418597">reactome:R-HSA-418597 </a> | G alpha (z) signalling events | Pathway |
| <a href="https://identifiers.org/CHEBI:17489">CHEBI:17489 </a> | 3,5-cyclic AMP | ChemicalSubstance |
| <a href="https://identifiers.org/GO:0042310">GO:0042310 </a> | vasoconstriction | BiologicalProcess |
| <a href="https://identifiers.org/HP:0031284">HP:0031284 </a> | Flushing | PhenotypicFeature |
| <a href="https://identifiers.org/HP:0001041">HP:0001041 </a> | Facial erythema | PhenotypicFeature |
| <a href="https://identifiers.org/MESH:D012393">MESH:D012393 </a> | Rosacea | Disease |
|------------|------|---------|

## Relationships


NOTE: predicates are annotated in <a href="https://github.com/biolink/biolink-model/releases/tag/v1.3.0">Biolink Model (v1.3.0)</a>

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Brimonidine | INCREASES ACTIVITY OF | Alpha-2A Adrenergic Receptor |
| Brimonidine | INCREASES ACTIVITY OF | Alpha-2B Adrenergic Receptor |
| Brimonidine | INCREASES ACTIVITY OF | Alpha-2C Adrenergic Receptor |
| Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (I) Signalling Events |
| Alpha-2A Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| Alpha-2B Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| Alpha-2C Adrenergic Receptor | PARTICIPATES IN | G Alpha (Z) Signalling Events |
| G Alpha (I) Signalling Events | DECREASES ABUNDANCE OF | 3,5-Cyclic Amp |
| G Alpha (Z) Signalling Events | DECREASES ABUNDANCE OF | 3,5-Cyclic Amp |
| 3,5-Cyclic Amp | NEGATIVELY CORRELATED WITH | Vasoconstriction |
| Vasoconstriction | NEGATIVELY CORRELATED WITH | Facial Erythema |
| Vasoconstriction | NEGATIVELY CORRELATED WITH | Flushing |
| Flushing | POSITIVELY CORRELATED WITH | Rosacea |
| Facial Erythema | POSITIVELY CORRELATED WITH | Rosacea |
|---------|-----------|---------|

Comment: The drug has an anti-inflammatory role which can help with treating some of the signs and symptoms of rosasea.

Reference: 
  - [https://go.drugbank.com/drugs/DB00484#mechanism-of-action](https://go.drugbank.com/drugs/DB00484#mechanism-of-action)
  - [https://en.wikipedia.org/wiki/Brimonidine#Mechanism_of_action](https://en.wikipedia.org/wiki/Brimonidine#Mechanism_of_action)
  - [https://en.wikipedia.org/wiki/Rosacea#Medications](https://en.wikipedia.org/wiki/Rosacea#Medications)
  - [https://pubmed.ncbi.nlm.nih.gov/26566370/](https://pubmed.ncbi.nlm.nih.gov/26566370/)
